Brain-charting autism and attention deficit hyperactivity disorder reveals distinct and overlapping neurobiology

Competing Interest Statement

EB reports consultancy work for Boehringer Ingelheim, Sosei Heptares, SR One, GlaxoSmithKline. EB, RAIB, JS, AFA-B are co-founders of Centile Bioscience. PAD receives research support from Biohaven Pharmaceuticals. M-CLai has received editorial honorarium from SAGE Publications. All other authors have nothing to declare. RN reported receiving grants from Brain Canada, Hoffman La Roche, Otsuka Pharmaceuticals, and Maplight Therapeutics outside the submitted work. EA reported receiving grants from Roche and Anavex; receiving nonfinancial support from AMO Pharma and CRA-Simons Foundation; and receiving personal fees from Roche, Impel, Ono, and Quadrant outside the submitted work; in addition, EA had a patent for Anxiety Meter issued 14/755/084 (United States) and a patent for Anxiety Meter pending 2,895,954 (Canada) as well as receiving royalties from APPI and Springer.

Funding Statement

SBC received funding from the Wellcome Trust 214322\Z\18\Z. For the purpose of Open Access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. The results leading to this publication have received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 777394 for the project AIMS-2-TRIALS. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA and AUTISM SPEAKS, Autistica, SFARI. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results. SBC also received funding from the Autism Centre of Excellence, SFARI, the Templeton World Charitable Fund and the MRC. All research at the Department of Psychiatry in the University of Cambridge was supported by the NIHR Cambridge Biomedical Research Centre (NIHR203312) and the NIHR Applied Research Collaboration East of England. Any views expressed are those of the author(s) and not necessarily those of the funders, IHU-JU2, the NIHR or the Department of Health and Social Care. EB was supported by an NIHR Cambridge Biomedical Research Centre and NIHR Senior Investigator award. PAD receives grant support from the Alberta Innovates Translational Health Chair in Child and Youth Mental Health, CIHR, Canadian Foundation for Innovation, and the Alberta Children's Hospital Foundation and research support from Biohaven Pharmaceuticals. M-CL is supported by the Academic Scholars Award from the Department of Psychiatry, University of Toronto, the Discovery Fund from the Centre for Addiction and Mental Health, and the Canadian Institutes of Health Research Sex and Gender Science Chair (GSB 171373). Funding was provided by the Ontario Brain Institute to EA and JPL. This work was also supported by NIDCD grant R01DC016385 awarded to EC and KP; and NIMH grant R01MH104446 awarded to KP. The Medical Research Council Autism Imaging Multicentre Study Consortium (MRC AIMS Consortium) is a UK collaboration between the Institute of Psychiatry, Psychology and Neuroscience (IoPPN) at King's College, London, the Autism Research Centre, University of Cambridge, and the Autism Research Group, University of Oxford. Members of MRC AIMS Consortium include: Anthony J. Bailey (Oxford), Simon Baron-Cohen (Cambridge), Patrick F. Bolton (IoPPN), Edward T. Bullmore (Cambridge), Sarah Carrington (Oxford), Marco Catani (IoPPN), Bhismadev Chakrabarti (Cambridge), Michael C. Craig (IoPPN), Eileen M. Daly (IoPPN), Sean C. L. Deoni (IoPPN), Christine Ecker (IoPPN), Francesca Happe (IoPPN), Julian Henty (Cambridge), Peter Jezzard (Oxford), Patrick Johnston (IoPPN), Derek K. Jones (IoPPN), Meng-Chuan Lai (Cambridge), Michael V. Lombardo (Cambridge), Anya Madden (IoPPN), Diane Mullins (IoPPN), Clodagh M. Murphy (IoPPN), Declan G. M. Murphy (IoPPN), Greg Pasco (Cambridge), Amber N. V. Ruigrok (Cambridge), Susan A. Sadek (Cambridge), Debbie Spain (IoPPN), Rose Stewart (Oxford), John Suckling (Cambridge), Sally J. Wheelwright (Cambridge) and Steven C. Williams (IoPPN).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethical approval and informed consent from all participants was obtained for each dataset in the primary study. The Cambridge Psychology Research Ethics Committee deemed secondary analysis of de-identified data not to require ethical oversight.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes